ConductScience.org, home

Paper42878985PubMed

GLP-1 Receptor Agonists and Lipoprotein (a): Insights, Gaps and Clinical Implications in Cardiovascular Diseases.

Mikhael FG and 6 others. Curr Atheroscler Rep, 2026.

Cite this record

ConductScience Library. GLP-1 Receptor Agonists and Lipoprotein (a): Insights, Gaps and Clinical Implications in Cardiovascular Diseases. Papers, record 42878985. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42878985

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
GLP-1 Receptor Agonists and Lipoprotein (a): Insights, Gaps and Clinical Implications in Cardiovascular Diseases.
Journal
Curr Atheroscler Rep
Year
2026
Publication types
Journal Article, Review
Revised in PubMed
2026-11-05

Source PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mikhael FGFady G
2Ayoub CChadi
3Teperikidis EEleftherios
4Biondi-Zoccai GGiuseppe
5Booz GWGeorge W
6Zouein FAFouad A
7Makarem NNNisrine N

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cardiovascular DiseasesMajor topic
Glucagon-Like Peptide-1 Receptor AgonistsMajor topic
Lipoprotein(a)Major topic
Hypoglycemic AgentsMajor topic
Humans
Animals
Biomarkers

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
Scholarly Concentration TrackFaculty of Medicine, American University of BeirutPubMed
University Research Board (URB)-103949; URB-104262; URB-104115; URB-104524; Medical Practice Plan (MPP)-320145Faculty of Medicine, American University of BeirutPubMed

Source PubMed

Download CSV of grants

References93

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132268367Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a).Eur Heart J2020https://conductscience.org/library/papers/32268367PubMed
222284365The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells.Atherosclerosis2012https://conductscience.org/library/papers/22284365PubMed
327345422The Cardiovascular Biology of Glucagon-like Peptide-1.Cell Metab2016https://conductscience.org/library/papers/27345422PubMed
420225248Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway.Hepatology2010https://conductscience.org/library/papers/20225248PubMed
535229024Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers.Alzheimers Dement (N Y)2022https://conductscience.org/library/papers/35229024PubMed
640781022Pelacarsen: Mechanism of action and Lp(a)-lowering effect.J Clin Lipidol2025https://conductscience.org/library/papers/40781022PubMed
735140289Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway.Sci Rep2022https://conductscience.org/library/papers/35140289PubMed
825014686Effects of extended-release niacin with laropiprant in high-risk patients.N Engl J Med2014https://conductscience.org/library/papers/25014686PubMed
941158620GLP-1 receptor agonists synergistic effects of metabolic reprogramming and cardioprotection.Front Endocrinol (Lausanne)2025https://conductscience.org/library/papers/41158620PubMed
1036977782Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action.Nat Rev Cardiol2023https://conductscience.org/library/papers/36977782PubMed
1134098057Effect of glucagon-like peptide-1 receptor agonists on circulating levels of leptin and resistin: A meta-analysis of randomized controlled trials.Diabetes Res Clin Pract2021https://conductscience.org/library/papers/34098057PubMed
1231965072Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study.Int J Obes (Lond)2020https://conductscience.org/library/papers/31965072PubMed
1321145820Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase.J Hepatol2011https://conductscience.org/library/papers/21145820PubMed
1436813656Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial.J Clin Lipidol2023https://conductscience.org/library/papers/36813656PubMed
1538832475Lipid profile changes induced by glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis.Expert Rev Clin Pharmacol2024https://conductscience.org/library/papers/38832475PubMed
1641086442Anti-inflammatory properties of GLP-1 receptor agonists and other ancillary benefits from a pharmacological perspective.Can J Physiol Pharmacol2025https://conductscience.org/library/papers/41086442PubMed
1737794465Chronic kidney outcomes associated with GLP-1 receptor agonists versus long-acting insulins among type 2 diabetes patients requiring intensive glycemic control: a nationwide cohort study.Cardiovasc Diabetol2023https://conductscience.org/library/papers/37794465PubMed
1823973688
Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).
J Am Coll Cardiol2013https://conductscience.org/library/papers/23973688PubMed
1936005135Liraglutide Exerts Protective Effects by Downregulation of PPARγ, ACSL1 and SREBP-1c in Huh7 Cell Culture Models of Non-Alcoholic Steatosis and Drug-Induced Steatosis.Curr Issues Mol Biol2022https://conductscience.org/library/papers/36005135PubMed
2035637990Effects of novel glucose-lowering drugs on the lipid parameters: A systematic review and meta-analysis.Ann Med Surg (Lond)2022https://conductscience.org/library/papers/35637990PubMed

See all 93 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42878985

GET https://conductscience.org/api/papers/v1/42878985/references?page=2